Welcome to our dedicated page for Bristol-Myers Squibb news (Ticker: BMY), a resource for investors and traders seeking the latest updates and insights on Bristol-Myers Squibb stock.
Bristol Myers Squibb reports news on its pharmaceutical portfolio across oncology, cardiovascular disease and immunology, including regulatory decisions, clinical trial data, commercial access programs and product collaborations. Company updates include Sotyktu (deucravacitinib), a selective TYK2 inhibitor approved in the European Union for active psoriatic arthritis, and Eliquis (apixaban), an oral anticoagulant marketed through the Bristol Myers Squibb-Pfizer alliance.
Recurring developments also cover quarterly financial results, investor conference participation, debt and capital-market activity, research collaborations in cardiovascular and precision-medicine programs, and community initiatives tied to multiple myeloma care. The company’s news flow combines product-specific regulatory milestones with broader disclosures on operating performance and pipeline partnerships.
Bristol Myers Squibb (NYSE:BMY) released new data on COVID-19 vaccine responses in participants treated with Zeposia (ozanimod) in the ongoing Phase 3 DAYBREAK trial for relapsing multiple sclerosis. The study indicated a 100% seroconversion rate in participants receiving mRNA vaccines, while 62% for non-mRNA vaccine recipients. Results show higher antibody levels in mRNA vaccine recipients, suggesting patients on Zeposia may benefit from booster doses. Findings will be presented on June 28, 2022, at the European Academy of Neurology Congress in Vienna.
Bristol Myers Squibb (NYSE: BMY) announced the validation of its type II variation application by the European Medicines Agency for Breyanzi to treat specific lymphoma types in adults, enhancing its role as a second-line therapy. This follows promising results from the TRANSFORM Phase 3 study, showcasing Breyanzi's superiority over the standard care with significant improvements in event-free survival and safety. The EMA review marks a critical step in advancing treatment options for patients with relapsed or refractory large B-cell lymphoma.
Bristol Myers Squibb (NYSE: BMY) announced a quarterly dividend of $0.54 per share on its common stock, payable on August 1, 2022, to stockholders of record by July 1, 2022. Additionally, a $0.50 dividend per share will be distributed on its convertible preferred stock, payable on September 1, 2022, to stockholders of record by August 9, 2022. The company continues its commitment to delivering value to its shareholders through consistent dividend payments.
Bristol Myers Squibb (NYSE: BMY) has appointed Dr. Deepak L. Bhatt to its Board of Directors, effective June 14, 2022. Dr. Bhatt, an expert in cardiovascular medicine, will also serve on the Science & Technology Committee. With over 20 years of research experience, he aims to enhance the company’s strategic development and innovation in treating serious diseases. This move expands the Board to 11 members, aligning with BMY's commitment to excellence in patient care and advancing its pipeline of medicines.
Bristol Myers Squibb (NYSE:BMY) is set to announce its second quarter 2022 financial results on July 27, 2022, at 8:00 a.m. ET. Company executives will host a conference call to review the results and answer questions from analysts and investors. A live webcast of the call will be accessible to the public via investor.bms.com. Replays of the call will be available starting at 11:30 a.m. EDT on the same day, continuing until August 10, 2022.
Bristol Myers Squibb (NYSE: BMY) will participate in a fireside chat at Goldman Sachs’ 43rd Annual Global Healthcare Conference in Rancho Palos Verdes, California, on Wednesday, June 15, 2022. Adam Lenkowsky, Senior VP and General Manager of U.S. Commercialization, will address questions starting at 9:20 a.m. PT/12:20 p.m. ET. Investors and the public can listen to a live webcast at investor.bms.com, where additional materials will also be available. An archived version will be accessible later that day.
Bristol Myers Squibb (NYSE: BMY) announced positive three-year follow-up results from the Phase 3 CheckMate -9LA trial for metastatic non-small cell lung cancer (mNSCLC). The trial demonstrated a significant improvement in overall survival (OS) with Opdivo and Yervoy, achieving a 27% survival rate compared to 19% for chemotherapy alone. Notably, results were favorable for patients with PD-L1 expression 1%. The safety profile remains consistent with previous findings. These findings underscore the potential of dual immunotherapy in addressing high unmet needs in mNSCLC.
Bristol Myers Squibb (BMY) reported five-year results from the Phase 3 CheckMate -227 trial, showing that the combination of Opdivo and Yervoy nearly doubled the overall survival rate at five years in patients with metastatic non-small cell lung cancer (mNSCLC) compared to chemotherapy. The five-year survival rate for patients with PD-L1 expression ≥1% was 24% for the immunotherapy combo, versus 14% for chemotherapy. In patients with PD-L1 expression 1%, survival rates were 19% vs. 7%. These results highlight the long-term efficacy and potential of and Yervoy as first-line treatments.
Bristol Myers Squibb (NYSE: BMY) announced the withdrawal of its supplemental biologics license application for Reblozyl (luspatercept-aamt) aimed at treating anemia in adults with non-transfusion dependent beta thalassemia. The decision comes after the FDA raised concerns regarding the drug's benefit-risk profile based on data from the Phase 2 BEYOND trial. Despite this setback, the company continues to advance Reblozyl through a broad clinical development program.
Bristol Myers Squibb (NYSE:BMY) announced an all-cash tender offer to acquire Turning Point Therapeutics (NASDAQ:TPTX) for $76.00 per share, valuing the deal at approximately $4.1 billion. The acquisition includes repotrectinib, a promising next-generation ROS1/NTRK inhibitor, expected to launch in 2023 and enhance BMY's oncology portfolio. The deal is anticipated to be accretive to non-GAAP earnings per share starting in 2025. Both companies' boards unanimously approved the transaction, expected to close in Q3 2022, subject to customary conditions.